R. E. Y. De Goede
University of Amsterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R. E. Y. De Goede.
The Lancet | 1989
M. Tersmette; R. E. Y. De Goede; J. M. A. Lange; F. de Wolf; J.K.M. Eeftink-Schattenkerk; P.Th.A. Schellekens; R. A. Coutinho; Jaap Goudsmit; J. G. Huisman; Frank Miedema
49 individuals seropositive for human immunodeficiency virus (HIV) antibody were studied longitudinally for the relation between in-vitro properties of their sequential HIV isolates and clinical course before and after the development of AIDS. They were classified into three groups according to the syncytium-inducing capacity, replication rate, and host range of their HIV isolates. The most rapid progression to AIDS (median 15 months) and the lowest survival rate following AIDS diagnosis (median survival 12.5 months) were observed in individuals with high-replicating, syncytium-inducing HIV isolates, followed by individuals with high-replicating, non-syncytium-inducing isolates. In contrast, most individuals with low-replicating, non-syncytium-inducing HIV isolates remained symptom-free during the study period (median follow-up until AIDS diagnosis greater than 42 months), and the few individuals from this group in whom AIDS developed were still alive at the end of the study period (median survival greater than 34 months). In addition, AIDS patients from the three groups differed with respect to their symptoms. Zidovudine treatment in the symptom-free period seemed to delay the onset of AIDS in all risk groups, although stabilisation of CD4+ cell numbers was observed only in individuals with non-syncytium-inducing HIV variants.
The Lancet | 1990
Charles A. Boucher; J. M. A. Lange; Jaap Goudsmit; Jan Mulder; M. Tersmette; R. E. Y. De Goede; Paul Kellam; Graham Darby; Brendan A. Larder
Human immunodeficiency type 1 isolates from 18 initially symptom-free men who were treated with zidovudine for 2 years were investigated for drug sensitivity. At the start all the men had persistent core antigenaemia; the acquired immunodeficiency syndrome developed in 6 during the study. The polymerase chain reaction was used to detect mutations at residue 215 of reverse transcriptase, a mutation associated with reduced drug sensitivity. After 2 years 16/18 isolates were mutant. However, after about 6 months of treatment the mutation was detected in only 7 isolates, 4 from individuals who subsequently had AIDS. Limited direct virus sensitivity data correlated with the genetic data. The rate of appearance of the 215 mutation seemed to correlate with CD4 counts and viral virulence.
AIDS | 1991
R. A. Gruters; Fokke G. Terpstra; R. E. Y. De Goede; Jan Mulder; F. de Wolf; P. T. A. Schellekens; R. A. W. Van Lier; M. Tersmette; Frank Miedema
Six men were selected from a large cohort of homosexual men participating in a study on HIV infection that was followed from seroconversion to AIDS. The patients were studied retrospectively for immunological functions of T cells, T-cell subset distribution and biological phenotype of HIV. A severe decrease in anti-CD3 monoclonal antibody (MAb)-induced T-cell proliferation at seroconversion was observed in two out of six men. After this acute phase, CD4+ T-cell numbers were in the normal range in the early asymptomatic period; the proliferative response was subnormal, whereas the capacity to generate cytotoxic T cells (CTL) was normal. From seroconversion on, CD4+CD29+ memory T-cell numbers were decreased to approximately 50% of normal values, which may contribute to loss of T-cell reactivity. In the asymptomatic phase only slow-replicating non-syncytium-inducing HIV variants were observed. The T-cell proliferative response further declined with the depletion of naive CD4+ CD45RA+ T cells and CD4+ T-cell numbers started to decline. This second decrease in T-cell function coincided with the emergence of more rapidly replicating, often (four out of six) syncytium-inducing variants. At diagnosis of AIDS, T-cell proliferation and CD4+ T-cell numbers were extremely low in five out of six patients and CTL function had declined in three out of five individuals tested. Circulating CD8+ cells had gradually shifted to an immature CD38+CD28- phenotype. Our findings support the theory that HIV-induced immune dysfunction allows for the emergence of virulent HIV variants associated with CD4+ cell loss and disease.
Virology | 1989
M. Tersmette; J J M van Dongen; Paul R. Clapham; R. E. Y. De Goede; Ingrid L. M. Wolvers-Tettero; A. Geurts van Kessel; J.G. Huisman; Robin A. Weiss; Frank Miedema
Human immunodeficiency virus (HIV) infection was studied by means of CD4-expressing human-murine T-cell hybrids, containing a variable amount of human chromosomes. Fusion of the HPRT- murine cell line BW5147 with human T-cell acute lymphoblastic leukemia or normal human blood cells resulted in a panel of human-murine T-cell hybrids. For this study, we used four hybrids containing all or several human chromosomes, which all expressed the CD4 antigen, as assessed by different anti-CD4 monoclonal antibodies (e.g., OKT4A, Leu-3a, and MT151) and, in addition, a variable number of other human T-cell antigens. For infection, HTLV-IIIB-infected H9 cells, pretreated with mitomycin C, and cell-free concentrated supernatants from these cells were used. In cells of inoculated cultures of the CD4+ T-cell hybrids, no viral antigen could be demonstrated. Culture supernatants of inoculated hybrids, except for an initial rise due to the virus inoculum, never showed reverse transcriptase activity above background. Cocultivation of these cell cultures with H9 cells did not result in detectable virus replication. Cocultivation of CD4-expressing hybrid cells with HIV-infected cells did not result in syncytium formation. Moreover, these hybrids were resistent to infection with vesicular stomatitis virus (VSV)-HIV pseudotypes. These findings imply that expression of the CD4 antigen on the cell surface is not sufficient for productive infection with HIV. The infectivity block observed in these hybrids seems to occur at the level of virus penetration, presumably at the stage of membrane fusion events.
Archive | 1985
W. L. E. Vasmel; Maarten Zijlstra; R. E. Y. De Goede; Harrie J. Schoenmakers; T. Radaszkiewics; C. J. M. Melief
H-2 congenic C57BL mice were inoculated neonatally with a panel of cloned ecotropic and MCF MuLV isolates. Lymphomas were characterized both for their histology and cell surface marker expression. The results indicate: 1) Synergism exists between ecotropic and MCF viruses in lymphomagenesis. 2) A single ecotropic or dualtropic MCF isolate causes a wide variety of T- and B-cell lymphomas. 3) Within a single mouse strain MuLV induced T-cell lymphomas arise earlier than B-cell lymphomas. 4) The H-2 complex influences lymphoma type. 5) The H-2 complex influences penetration of the thymus by thymotropic MCF virus. 6) These H-2 effects are correlated with H-2 linked differences in the immune responses against both MuLV particles and MuLV-infected cells. A model in which the level of the immune response is one of the main factors determining lymphoma phenotype will be discussed.
Journal of Virology | 1992
Hanneke Schuitemaker; Maarten Koot; Neeltje A. Kootstra; M W Dercksen; R. E. Y. De Goede; R P van Steenwijk; Joep M. A. Lange; J K Schattenkerk; Frank Miedema; M. Tersmette
Journal of Virology | 1989
M. Tersmette; Rob A. Gruters; F. de Wolf; R. E. Y. De Goede; J. M. A. Lange; P. T. A. Schellekens; Jaap Goudsmit; Han G. Huisman; Frank Miedema
Journal of Virology | 1988
M. Tersmette; R. E. Y. De Goede; B J Al; I N Winkel; Rob A. Gruters; H T Cuypers; Han G. Huisman; Frank Miedema
Journal of Virology | 1991
Hanneke Schuitemaker; Neeltje A. Kootstra; R. E. Y. De Goede; F. de Wolf; Frank Miedema; M. Tersmette
Journal of Virology | 1992
Martijn Groenink; Arno C. Andeweg; R. A. M. Fouchier; S. Broersen; R. C. M. Van Der Jagt; Hanneke Schuitemaker; R. E. Y. De Goede; Marnix L. Bosch; Han G. Huisman; M. Tersmette